Litcius/Paper detail

Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS)

Helly Hammer, Nicole Kamber, Maximilian Pistor, Lara Diem, Christoph Friedli, Andrew Chan, Robert Hoepner, Anke Salmen

2022Multiple Sclerosis and Related Disorders16 citationsDOI

Topics & Concepts

MedicineNeutropeniaAdverse Event Reporting SystemOcrelizumabInternal medicineLogistic regressionAdverse effectPharmacovigilanceDatabaseRituximabChemotherapyLymphomaComputer scienceBlood disorders and treatmentsPharmacovigilance and Adverse Drug ReactionsBiosimilars and Bioanalytical Methods
Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS) | Litcius